fill
Listen On
Hepatology

What is Resmetirom and how does it work to treat MASH?

Thank you to Madrigal for sponsoring the Medication Review Video Module.

In this GHAPP Medication Review video, Robin Soto, a board-certified nurse practitioner at UC San Diego Health Hepatology, explains the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of MASH in adults with mild to moderate fibrosis (F2-F3). Robin describes how Resmetirom, a liver-directed, thyroid hormone receptor beta agonist, targets liver fat accumulation, promoting fatty acid oxidation and improving cholesterol metabolism. She highlights its anti-inflammatory effects and ability to reduce liver fibrosis by selectively activating receptors in the liver, while minimizing systemic side effects.

Related Medical Review Videos Module

sectionimg
dotimg

Download the app and start using it now

© 2024 Gastroenterology & Hepatology Advance Practice Providers, All rights reserved.